In a 75-year-old male nursing home resident with dementia (or remote Wernicke’s encephalopathy) who exhibits severe agitation, aggression, wandering, disinhibition, and inappropriate sexual behavior refractory to nonpharmacologic interventions and trazodone, what is the most likely diagnosis and which psychotropic medication is best indicated?

Diagnosis and Treatment Recommendation

This patient has severe behavioral and psychological symptoms of dementia (BPSD) with prominent disinhibition, and an antipsychotic medication should be initiated given the severity, dangerousness, and failure of non-pharmacological interventions and trazodone. 1

Diagnosis

The clinical picture represents severe BPSD with prominent disinhibition manifesting as:

• Aggression and hostility toward staff and residents
• Sexual disinhibition (disrobing, inappropriate nudity)
• Wandering and intrusive behaviors
• Agitation refractory to behavioral interventions

Research confirms that extreme sexual behavior in dementia is not an independent symptom but rather a specific manifestation of disinhibition 2. The constellation of aggression, sexual disinhibition, and behavioral dyscontrol all point to disinhibition as the core neuropsychiatric symptom 3.

Rationale for Antipsychotic Use

The APA guidelines explicitly state that antipsychotic medication should be used when symptoms are severe, dangerous, and/or cause significant distress 1. This patient meets all three criteria:

• Severe: Multiple refractory symptoms affecting daily function
• Dangerous: Escalation to violence, risk to staff and other residents
• Distressing: To both the patient and the nursing home community

The guidelines confirm that non-pharmacological interventions should be attempted first 1, which has been done. Trazodone was appropriately tried but provided only partial benefit (reduced agitation but persistent aggression and disinhibition). The evidence shows trazodone has insufficient efficacy for behavioral manifestations of dementia 4, and it is not indicated for disinhibition or aggression beyond its mild sedative effects 5.

Recommended Antipsychotic Approach

Initiate a low-dose atypical antipsychotic, starting with risperidone 0.25-0.5 mg daily or quetiapine 12.5-25 mg daily, titrating slowly to the minimum effective dose 1.

Specific Medication Considerations:

Quetiapine may be preferred based on recent evidence showing it had the lowest frequency of adverse events among antipsychotics in older adults (OR 0.27 compared to haloperidol) 6. This is particularly relevant given this patient's age and nursing home setting.

Avoid benzodiazepines entirely - the 2025 geriatric emergency guidelines found that benzodiazepines, particularly midazolam, pose excessive risk to older adults with severe agitation (OR 5.25 for adverse events compared to haloperidol) 6.

Implementation Algorithm:

1. Before initiating: Discuss risks and benefits with the patient's surrogate decision maker and family, documenting the conversation 1

   • Emphasize increased mortality risk with antipsychotics in dementia
   • Explain that benefits are modest but may prevent harm
   • Document that non-pharmacological approaches and trazodone have failed

2. Starting dose:

   • Quetiapine 12.5-25 mg at bedtime, OR
   • Risperidone 0.25 mg at bedtime

3. Titration: Increase every 3-5 days as tolerated to minimum effective dose 1

4. Monitoring: Use a quantitative measure (e.g., Cohen-Mansfield Agitation Inventory, Neuropsychiatric Inventory) to track response 1

5. Reassessment timeline:

   • If no response after 4 weeks at adequate dose: taper and discontinue 1
   • If significant side effects occur: reassess risk/benefit and consider tapering 1
   • If effective: attempt gradual taper after 3-4 months of stability, with ongoing monitoring

Critical Pitfalls to Avoid

• Do not use typical antipsychotics (haloperidol) as first-line - they have higher adverse event rates in geriatric patients 6
• Do not add benzodiazepines - they dramatically increase adverse events in this population 6
• Do not continue indefinitely without reassessment - the guidelines mandate regular attempts at dose reduction once symptoms stabilize 1
• Do not use trazodone as monotherapy for aggression/disinhibition - evidence shows it is ineffective for these specific symptoms 4
• Monitor for QT prolongation if combining with other QT-prolonging medications 5

Additional Considerations

Ensure medical workup has excluded delirium, pain, infection, constipation, or medication side effects as contributors 1, 3. Given the history of remote Wernicke's encephalopathy, verify thiamine supplementation is adequate, though this is unlikely to be driving current behavioral symptoms 7, 8.

The goal is minimal sedation allowing safe participation in care, not complete behavioral suppression 6. Document specific target behaviors and reassess weekly initially, then monthly once stable.